InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,638.88
(
-0.02%
)
Post# of 252496
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

semi_infinite

Send PM Follow Ignore
Followers 14
Posts 3822
Boards Moderated 1
Alias Born 07/07/2002

semi_infinite

Re: dewophile post# 244413

Friday, 11/04/2022 10:49:30 AM

Friday, November 04, 2022 10:49:30 AM

Post# of 252496
No. They need to prove that new partner, Artiva cbNK cells, works like MDACC cbNK. Artiva collaboration was announced 2 years ago and it was Sept that they had sufficient data to close the deal. FDA 2nd mtg beginning of year and IND filing after that.

The ~6000 initial market includes AFM13 mono and combo with PD-1. ~2000 r/r HL would be addressable with AFM13-cbNK.

What do you think would be more realistic if above are not IYO?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up